The current financial score of Novavax Inc is 7.26. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 56.70M, representing a year-over-year decrease of 76.30%, while its net profit experienced a year-over-year decrease of 150.12%.
The current valuation score of Novavax Inc is 9.34. Its current P/E ratio is -18.04, which is -126.22% below the recent high of 4.73 and -9.69% above the recent low of -19.79.
The current earnings forecast score of Novavax Inc is 6.67. The average price target is 14.00, with a high of 25.00 and a low of 7.00.
The current price momentum score of Novavax Inc is 5.85. Currently, the stock price is trading between the resistance level at 11.15 and the support level at 8.66, making it suitable for range-bound swing trading.
The current institutional shareholding score of Novavax Inc is 7.00. The latest institutional shareholding proportion is 77.98%, representing a quarter-over-quarter increase of 22.65%. The largest institutional shareholder is Philippe Laffont, holding a total of 3.84M shares, representing 0.07% of shares outstanding, with 1.00% increase in holdings.
The current risk assessment score of Novavax Inc is 6.08. The company's beta value is 2.42. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.